Current diagnosis and treatment of arterial hypertension induced by antiangiogenic antitumour agents

Abstract

The use of angiogenesis inhibitors (anti-VGEF antibodies and tyrosine kinase inhibitors) in oncology significantly increases both the tumor response to therapy and the risk of cardiovascular toxicity. Arterial hypertension is the main adverse effect of antiangiogenic therapy frequently limiting the doses of angiogenesis inhibitors, although it is also considered as a possible surrogate marker of the effectiveness of targeted therapy. In 2022, the recommendations of the European Society of Cardiology on the prevention and correction of cardiotoxicity of antitumor therapy were published. The article reviews the current diagnosis and treatment of arterial hypertension induced by antiangiogenic medicines.